57
In a major move aimed at increasing accessibility and affordability, Novo Nordisk—the Denmark-based pharmaceutical giant behind the blockbuster weight loss drug Wegovy—announces a significant price reduction and a broader distribution model. The company says it will now collaborate with telehealth providers to offer a more affordable pathway for patients seeking anti-obesity treatment.
Starting immediately, patients can access name-brand Wegovy injections delivered directly to their homes for $499 per month, plus an estimated $100 in telehealth service fees. This new combined monthly cost of approximately. . .
